Progress in the clinical application of immune checkpoint inhibitors in small cell lung cancer

HIGHLIGHTS

• who: Jiahui He and Qinyong Hu from the Medical University of Warsaw, Poland have published the research: Progress in the clinical application of immune checkpoint inhibitors in small cell lung cancer, in the Journal: (JOURNAL) of October/28,/2027
• what: The results of this study showed that the ORR was 33%, the median OS was 7.7 months, the PFS was 1.9 months, and the 1-year survival rate was 37.7%.
• how: These results showed that there was no significant improvement in the primary endpoint of OS compared with chemotherapy alone . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.